Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.78 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.78 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.78 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10330219 | 0.93 | GUCY1B2 (0.81) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3436919 | 0.90 | GUCY1B2 (0.68) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3436902 | 0.90 | GUCY1B2 (0.82) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3439299 | 0.88 | GUCY1B2 (1.00) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL29778216 | 0.88 | GUCY1B2 (1.00) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL15087534 | 0.87 | GUCY1B2 (0.84) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3436772 | 0.87 | GUCY1B2 (0.84) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3436905 | 0.87 | GUCY1B2 (0.87) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL15780017 | 0.87 | GUCY1B2 (0.87) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 | |
| SCHEMBL3437391 | 0.87 | GUCY1B2 (0.80) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345130-A1 | SGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345130-A1 | SGC STIMULATORS | GUCY1A1, PTGIS, GUCY1B1 | GUCY1B2 6/4885GUCY1A2 4/4885GUCY1A1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.